

Caroline Robert

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6937738/publications.pdf>

Version: 2024-02-01

494
papers

123,076
citations

416

132
h-index

125

338
g-index

536
all docs

536
docs citations

536
times ranked

71538
citing authors

#	ARTICLE	IF	CITATIONS
1	Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. <i>New England Journal of Medicine</i> , 2010, 363, 711-723.	13.9	13,065
2	Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. <i>New England Journal of Medicine</i> , 2011, 364, 2507-2516.	13.9	6,976
3	PD-1 blockade induces responses by inhibiting adaptive immune resistance. <i>Nature</i> , 2014, 515, 568-571.	13.7	5,429
4	Pembrolizumab versus Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2015, 372, 2521-2532.	13.9	4,838
5	Nivolumab in Previously Untreated Melanoma without BRAF Mutation. <i>New England Journal of Medicine</i> , 2015, 372, 320-330.	13.9	4,795
6	Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma. <i>New England Journal of Medicine</i> , 2011, 364, 2517-2526.	13.9	4,074
7	Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma. <i>New England Journal of Medicine</i> , 2013, 369, 134-144.	13.9	3,128
8	Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. <i>Science</i> , 2015, 350, 1079-1084.	6.0	2,539
9	Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma. <i>New England Journal of Medicine</i> , 2015, 372, 2006-2017.	13.9	2,489
10	Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib. <i>New England Journal of Medicine</i> , 2015, 372, 30-39.	13.9	2,240
11	Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma. <i>New England Journal of Medicine</i> , 2012, 367, 107-114.	13.9	1,976
12	Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 1889-1894.	0.8	1,809
13	Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2017, 28, iv119-iv142.	0.6	1,744
14	Immune-related adverse events with immune checkpoint blockade: a comprehensive review. <i>European Journal of Cancer</i> , 2016, 54, 139-148.	1.3	1,687
15	Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. <i>Lancet</i> , 2014, 384, 1109-1117.	6.3	1,588
16	Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. <i>New England Journal of Medicine</i> , 2014, 371, 1877-1888.	13.9	1,572
17	Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. , 2017, 5, 95.		1,460
18	Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. <i>New England Journal of Medicine</i> , 2018, 378, 1789-1801.	13.9	1,441

#	ARTICLE	IF	CITATIONS
19	Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 908-918.	5.1	1,419
20	Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1813-1823.	13.9	1,192
21	Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet</i> , The, 2015, 386, 444-451.	6.3	1,175
22	Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. <i>New England Journal of Medicine</i> , 2016, 375, 1845-1855.	13.9	1,140
23	Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC Tj ETQq1 1 0,784314 rrgBT /Overle	5.1	1,093
24	Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 25-35.	0.8	1,088
25	Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). <i>Lancet</i> , The, 2017, 390, 1853-1862.	6.3	1,032
26	Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of the first phase I clinical trial. <i>Journal of Translational Medicine</i> , 2005, 3, 10.	1.8	993
27	Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 785-792.	0.8	930
28	A decade of immune-checkpoint inhibitors in cancer therapy. <i>Nature Communications</i> , 2020, 11, 3801.	5.8	920
29	Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. <i>New England Journal of Medicine</i> , 2019, 381, 626-636.	13.9	909
30	Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. <i>Annals of Oncology</i> , 2017, 28, 1368-1379.	0.6	908
31	Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. <i>Lancet Oncology</i> , The, 2014, 15, 323-332.	5.1	890
32	Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1600.	3.8	857
33	Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2012, 13, 1087-1095.	5.1	841
34	Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 473-486.	12.5	831
35	Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1558-1568.	5.1	827
36	Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2019, 20, 1239-1251.	5.1	812

#	ARTICLE	IF	CITATIONS
37	CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor- β dependent manner. <i>Journal of Experimental Medicine</i> , 2005, 202, 1075-1085.	4.2	806
38	Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 603-615.	5.1	751
39	Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. <i>Annals of Oncology</i> , 2016, 27, 559-574.	0.6	749
40	Electrochemotherapy – An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. <i>European Journal of Cancer, Supplement</i> , 2006, 4, 3-13.	2.2	713
41	Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. <i>Nature</i> , 2014, 508, 118-122.	13.7	702
42	Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. <i>Annals of Oncology</i> , 2019, 30, 582-588.	0.6	641
43	Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. <i>Journal of Clinical Oncology</i> , 2016, 34, 1510-1517.	0.8	627
44	Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. <i>Lancet Oncology, The</i> , 2019, 20, 1083-1097.	5.1	611
45	CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients. <i>Clinical Cancer Research</i> , 2013, 19, 5300-5309.	3.2	596
46	Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , 2017, 18, 863-873.	5.1	561
47	Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. <i>Annals of Oncology</i> , 2017, 28, 1631-1639.	0.6	549
48	Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab. <i>JAMA Dermatology</i> , 2016, 152, 45.	2.0	539
49	Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 4102-4109.	0.8	528
50	Cutaneous side-effects of kinase inhibitors and blocking antibodies. <i>Lancet Oncology, The</i> , 2005, 6, 491-500.	5.1	527
51	Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology. <i>Annals of Oncology</i> , 2017, 28, 1191-1206.	0.6	520
52	Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 2823-2830.	0.8	517
53	Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2018, 19, 1315-1327.	5.1	469
54	A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. <i>Nature</i> , 2011, 480, 94-98.	13.7	466

#	ARTICLE	IF	CITATIONS
55	Cutaneous melanoma. <i>Lancet</i> , The, 2014, 383, 816-827.	6.3	465
56	Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 1191-1196.	0.8	445
57	Inflammatory Skin Diseases, T Cells, and Immune Surveillance. <i>New England Journal of Medicine</i> , 1999, 341, 1817-1828.	13.9	435
58	Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 611-622.	5.1	428
59	Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet</i> , The, 2020, 395, 1835-1844.	6.3	423
60	The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network. <i>PLoS ONE</i> , 2013, 8, e53745.	1.1	414
61	Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. <i>Journal of Hepatology</i> , 2018, 68, 1181-1190.	1.8	372
62	<i>RAS</i> Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors. <i>Journal of Clinical Oncology</i> , 2012, 30, 316-321.	0.8	366
63	Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. <i>Journal of Clinical Oncology</i> , 2017, 35, 3807-3814.	0.8	364
64	Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 1668-1674.	0.8	360
65	Dendritic Cell-Derived Exosomes Promote Natural Killer Cell Activation and Proliferation: A Role for NKG2D Ligands and IL-15. <i>PLoS ONE</i> , 2009, 4, e4942.	1.1	352
66	Evolving Strategies for the Management of Hand-Foot Skin Reaction Associated with the Multitargeted Kinase Inhibitors Sorafenib and Sunitinib. <i>Oncologist</i> , 2008, 13, 1001-1011.	1.9	315
67	Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. <i>Annals of Oncology</i> , 2007, 18, 2030-2036.	0.6	307
68	Survival Outcomes in Patients With Previously Untreated <i>BRAF</i> Wild-Type Advanced Melanoma Treated With Nivolumab Therapy. <i>JAMA Oncology</i> , 2019, 5, 187.	3.4	295
69	Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody. <i>Clinical Cancer Research</i> , 2017, 23, 1929-1936.	3.2	290
70	eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. <i>Nature</i> , 2014, 513, 105-109.	13.7	287
71	Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo. <i>JAMA Oncology</i> , 2020, 6, 519.	3.4	287
72	Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. <i>Annals of Oncology</i> , 2013, 24, 1697-1703.	0.6	280

#	ARTICLE	IF	CITATIONS
73	Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report. <i>Annals of Oncology</i> , 2020, 31, 961-964.	0.6	280
74	MHC Class I-Related Neonatal Fc Receptor for IgG Is Functionally Expressed in Monocytes, Intestinal Macrophages, and Dendritic Cells. <i>Journal of Immunology</i> , 2001, 166, 3266-3276.	0.4	279
75	Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 395-401.	0.6	274
76	Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. <i>Annals of the New York Academy of Sciences</i> , 2013, 1291, 1-13.	1.8	270
77	Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma. <i>Clinical Cancer Research</i> , 2012, 18, 555-567.	3.2	267
78	Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. <i>Lancet Oncology</i> , The, 2016, 17, 1743-1754.	5.1	266
79	Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 867-875.	0.8	258
80	Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. <i>New England Journal of Medicine</i> , 2020, 383, 1139-1148.	13.9	256
81	Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 3810-3818.	0.8	254
82	Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. <i>Journal of Clinical Investigation</i> , 2004, 114, 379-388.	3.9	248
83	Survival of patients with advanced metastatic melanoma: the impact of novel therapies—update 2017. <i>European Journal of Cancer</i> , 2017, 83, 247-257.	1.3	236
84	Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. <i>Lancet</i> , The, 2022, 399, 1718-1729.	6.3	236
85	Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer. <i>Nature Communications</i> , 2020, 11, 2168.	5.8	231
86	Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. <i>Cancer Treatment Reviews</i> , 2017, 58, 70-76.	3.4	228
87	Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma. <i>Clinical Cancer Research</i> , 2010, 16, 1042-1048.	3.2	227
88	Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected <i>BRAF</i> V600E Mutant Stage III Melanoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 3441-3449.	0.8	226
89	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 643-654.	5.1	224
90	Senescent cells develop a PARP-1 and nuclear factor- κ B-associated secretome (PNAS). <i>Genes and Development</i> , 2011, 25, 1245-1261.	2.7	223

#	ARTICLE	IF	CITATIONS
91	Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. <i>Clinical Cancer Research</i> , 2018, 24, 4960-4967.	3.2	222
92	Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. <i>European Journal of Cancer</i> , 2018, 91, 21-29.	1.3	222
93	Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type. <i>Archives of Dermatology</i> , 2007, 143, 1144-50.	1.7	218
94	Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. <i>Lancet Oncology</i> , The, 2015, 16, 1389-1398.	5.1	206
95	Prospective Study of the Cutaneous Adverse Effects of Sorafenib, a Novel Multikinase Inhibitor. <i>Archives of Dermatology</i> , 2008, 144, 886-92.	1.7	204
96	Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 2100-2111.	2.9	202
97	Compounds Triggering ER Stress Exert Anti-Melanoma Effects and Overcome BRAF Inhibitor Resistance. <i>Cancer Cell</i> , 2016, 29, 805-819.	7.7	201
98	Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. <i>Annals of Oncology</i> , 2017, 28, 2581-2587.	0.6	201
99	Targeted Therapies for Renal Cell Carcinoma: Review of Adverse Event Management Strategies. <i>Journal of the National Cancer Institute</i> , 2012, 104, 93-113.	3.0	197
100	Prognosis in Patients With Sentinel Node-Positive Melanoma Is Accurately Defined by the Combined Rotterdam Tumor Load and Dewar Topography Criteria. <i>Journal of Clinical Oncology</i> , 2011, 29, 2206-2214.	0.8	195
101	Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. <i>Lancet Haematology</i> , the, 2019, 6, e48-e57.	2.2	195
102	Analysis of Dermatologic Events in Vemurafenib-Treated Patients With Melanoma. <i>Oncologist</i> , 2013, 18, 314-322.	1.9	192
103	Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 3925-3936.	0.8	192
104	Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. <i>Annals of Oncology</i> , 2008, 19, 142-149.	0.6	190
105	Systemic Therapy for Melanoma: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 3947-3970.	0.8	190
106	Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032). <i>European Journal of Cancer</i> , 2011, 47, 1476-1483.	1.3	189
107	Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 2413-2420.	0.8	188
108	Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. <i>European Journal of Cancer</i> , 2017, 86, 37-45.	1.3	183

#	ARTICLE	IF	CITATIONS
109	Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. <i>European Journal of Cancer</i> , 2012, 48, 218-225.	1.3	182
110	Final Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 1211-1218.	0.8	182
111	Natural Killer Cell IFN- γ Levels Predict Long-term Survival with Imatinib Mesylate Therapy in Gastrointestinal Stromal Tumor-bearing Patients. <i>Cancer Research</i> , 2009, 69, 3563-3569.	0.4	181
112	Targeting autophagy inhibits melanoma growth by enhancing NK cells infiltration in a CCL5-dependent manner. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E9271-E9279.	3.3	181
113	Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma. <i>Nature Medicine</i> , 2018, 24, 1877-1886.	15.2	180
114	Enterocolitis due to immune checkpoint inhibitors: a systematic review. <i>Gut</i> , 2018, 67, 2056-2067.	6.1	179
115	Hand-Foot Syndrome (Hand-Foot Skin Reaction, Palmar-Plantar Erythrodysesthesia): Focus on Sorafenib and Sunitinib. <i>Oncology</i> , 2009, 77, 257-271.	0.9	177
116	Interleukin-1 and Cutaneous Inflammation: A Crucial Link Between Innate and Acquired Immunity. <i>Journal of Investigative Dermatology</i> , 2000, 114, 602-608.	0.3	173
117	Interaction of Dendritic Cells with Skin Endothelium: A New Perspective on Immunosurveillance. <i>Journal of Experimental Medicine</i> , 1999, 189, 627-636.	4.2	172
118	Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. <i>Annals of Oncology</i> , 2013, 24, 1691-1697.	0.6	172
119	New drugs in melanoma: It's a whole new world. <i>European Journal of Cancer</i> , 2011, 47, 2150-2157.	1.3	168
120	Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. <i>European Journal of Cancer</i> , 2017, 82, 45-55.	1.3	160
121	Persistent Cancer Cells: The Deadly Survivors. <i>Cell</i> , 2020, 183, 860-874.	13.5	157
122	Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. <i>Nephrology Dialysis Transplantation</i> , 2008, 24, 682-685.	0.4	155
123	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology</i> , The, 2019, 20, e378-e389.	5.1	155
124	Kidney injuries related to ipilimumab. <i>Investigational New Drugs</i> , 2014, 32, 769-773.	1.2	153
125	Keratoacanthomas and Squamous Cell Carcinomas in Patients Receiving Sorafenib. <i>Journal of Clinical Oncology</i> , 2009, 27, e59-e61.	0.8	152
126	Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. <i>Lancet Oncology</i> , The, 2013, 14, 733-740.	5.1	151

#	ARTICLE	IF	CITATIONS
127	Immune Checkpoint Inhibitors. <i>Progress in Tumor Research</i> , 2015, 42, 55-66.	0.1	151
128	Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 848-857.	5.1	150
129	Impact of Surgery on Advanced Gastrointestinal Stromal Tumors (GIST) in the Imatinib Era. <i>Annals of Surgical Oncology</i> , 2006, 13, 1596-1603.	0.7	149
130	Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis. <i>European Journal of Cancer</i> , 2017, 82, 34-44.	1.3	146
131	Efficacy and Safety of Retreatment with Ipilimumab in Patients with Pretreated Advanced Melanoma Who Progressed after Initially Achieving Disease Control. <i>Clinical Cancer Research</i> , 2013, 19, 2232-2239.	3.2	145
132	Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT). <i>Annals of Oncology</i> , 2018, 29, 2163-2174.	0.6	145
133	Cyclophosphamide Induces Differentiation of Th17 Cells in Cancer Patients. <i>Cancer Research</i> , 2011, 71, 661-665.	0.4	144
134	Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. <i>Cell Research</i> , 2015, 25, 208-224.	5.7	143
135	Dermatologic symptoms associated with the multikinase inhibitor sorafenib. <i>Journal of the American Academy of Dermatology</i> , 2009, 60, 299-305.	0.6	142
136	Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma. <i>Clinical Cancer Research</i> , 2017, 23, 5339-5348.	3.2	142
137	Nail toxicities induced by systemic anticancer treatments. <i>Lancet Oncology</i> , The, 2015, 16, e181-e189.	5.1	139
138	Survival of patients with advanced metastatic melanoma: The impact of novel therapies. <i>European Journal of Cancer</i> , 2016, 53, 125-134.	1.3	137
139	Phase I Trial of Sorafenib in Combination with IFN γ 2a in Patients with Unresectable and/or Metastatic Renal Cell Carcinoma or Malignant Melanoma. <i>Clinical Cancer Research</i> , 2007, 13, 1801-1809.	3.2	136
140	Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. <i>European Journal of Cancer</i> , 2019, 119, 1-10.	1.3	132
141	ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. <i>Annals of Oncology</i> , 2020, 31, 1435-1448.	0.6	132
142	Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression. <i>JAMA Oncology</i> , 2017, 3, 1511.	3.4	131
143	Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600E mutant melanoma. <i>European Journal of Cancer</i> , 2020, 126, 33-44.	1.3	130
144	Prognostic Factors of Paraneoplastic Pemphigus. <i>Archives of Dermatology</i> , 2012, 148, 1165.	1.7	125

#	ARTICLE	IF	CITATIONS
145	Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors. <i>British Journal of Dermatology</i> , 2009, 161, 515-521.	1.4	120
146	Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3003-3003.	0.8	120
147	Skin Tumors Induced by Sorafenib; Paradoxical RASâ€“RAF Pathway Activation and Oncogenic Mutations of <i>HRAS</i> , <i>TP53</i> , and <i>TGFBR1</i> . <i>Clinical Cancer Research</i> , 2012, 18, 263-272.	3.2	119
148	Five-Year Outcomes With Nivolumab in Patients With Wild-Type <i>BRAF</i> Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3937-3946.	0.8	119
149	Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1238-1246.	0.6	116
150	Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF- α be better?. <i>Annals of Oncology</i> , 2005, 16, 1061-1068.	0.6	115
151	Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies. <i>Annals of Oncology</i> , 2017, 28, 2860-2865.	0.6	115
152	Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. <i>British Journal of Cancer</i> , 2018, 119, 670-674.	2.9	114
153	RAF inhibition and induction of cutaneous squamous cell carcinoma. <i>Current Opinion in Oncology</i> , 2011, 23, 177-182.	1.1	111
154	Tumour burden and efficacy of immune-checkpoint inhibitors. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 75-90.	12.5	111
155	What Is the Role of Cytotoxic T Lymphocyteâ€“Associated Antigen 4 Blockade in Patients with Metastatic Melanoma?. <i>Oncologist</i> , 2009, 14, 848-861.	1.9	109
156	CTLA-4 Blockade Confers Lymphocyte Resistance to Regulatory T-Cells in Advanced Melanoma: Surrogate Marker of Efficacy of Tremelimumab?. <i>Clinical Cancer Research</i> , 2008, 14, 5242-5249.	3.2	104
157	Search for Evidence-Based Approaches for the Prevention and Palliation of Handâ€“Foot Skin Reaction (HFSR) Caused by the Multikinase Inhibitors (MKIs). <i>Oncologist</i> , 2009, 14, 291-302.	1.9	103
158	AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study. <i>Journal of Clinical Oncology</i> , 2008, 26, 9033-9033.	0.8	103
159	Cell Survival and Shuttle Vector Mutagenesis Induced by Ultraviolet A and Ultraviolet B Radiation in a Human Cell Line. <i>Journal of Investigative Dermatology</i> , 1996, 106, 721-728.	0.3	101
160	Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial. <i>European Journal of Cancer</i> , 2018, 101, 236-243.	1.3	100
161	The plasticity of mRNA translation during cancer progression and therapy resistance. <i>Nature Reviews Cancer</i> , 2021, 21, 558-577.	12.8	100
162	Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9503-9503.	0.8	98

#	ARTICLE	IF	CITATIONS
163	Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy. <i>Cancer Cell</i> , 2022, 40, 318-334.e9.	7.7	97
164	Long-Term Survival in Patients Responding to Anti-PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation. <i>Clinical Cancer Research</i> , 2019, 25, 946-956.	3.2	96
165	Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2298-2310.	3.3	95
166	Selective Accumulation of Mature DC-Lamp+ Dendritic Cells in Tumor Sites Is Associated with Efficient T-Cell-Mediated Antitumor Response and Control of Metastatic Dissemination in Melanoma. <i>Cancer Research</i> , 2004, 64, 2192-2198.	0.4	94
167	Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study. <i>Annals of Oncology</i> , 2016, 27, 1940-1946.	0.6	94
168	Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. <i>Lancet Oncology</i> , 2020, 21, 358-372.	5.1	94
169	Melanoma-associated fibroblasts decrease tumor cell susceptibility to NK cell-mediated killing through matrix-metalloproteinases secretion. <i>Oncotarget</i> , 2017, 8, 19780-19794.	0.8	92
170	Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , 2017, 18, 393-403.	5.1	91
171	Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600E Mutant Unresectable or Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 1428-1438.	0.8	90
172	Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies. <i>Annals of Oncology</i> , 2016, 27, 214-224.	0.6	86
173	Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAF V600E-mutated melanoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 8502-8502.	0.8	86
174	Drug of the year: Programmed Death-1 receptor/Programmed Death-1 Ligand-1 receptor monoclonal antibodies. <i>European Journal of Cancer</i> , 2013, 49, 2968-2971.	1.3	84
175	Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019. <i>European Journal of Cancer</i> , 2020, 130, 126-138.	1.3	84
176	Vemurafenib and Radiosensitization. <i>JAMA Dermatology</i> , 2013, 149, 855.	2.0	83
177	Genetic variability and integration of Merkel cell polyomavirus in Merkel cell carcinoma. <i>Virology</i> , 2012, 426, 134-142.	1.1	82
178	Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i. <i>Nature Medicine</i> , 2020, 26, 1557-1563.	15.2	78
179	Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. <i>European Journal of Cancer</i> , 2016, 67, 46-54.	1.3	77
180	Melanoma Persister Cells Are Tolerant to BRAF/MEK Inhibitors via ACOX1-Mediated Fatty Acid Oxidation. <i>Cell Reports</i> , 2020, 33, 108421.	2.9	77

#	ARTICLE	IF	CITATIONS
181	New Functional Signatures for Understanding Melanoma Biology from Tumor Cell Lineage-Specific Analysis. <i>Cell Reports</i> , 2015, 13, 840-853.	2.9	76
182	Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma. <i>European Journal of Cancer</i> , 2017, 86, 115-124.	1.3	76
183	Immature mouse dendritic cells enter inflamed tissue, a process that requires E- and P-selectin, but not P-selectin glycoprotein ligand 1. <i>Blood</i> , 2002, 99, 946-956.	0.6	75
184	Small molecules and targeted therapies in distant metastatic disease. <i>Annals of Oncology</i> , 2009, 20, vi35-vi40.	0.6	75
185	Molecular Pathways: The eIF4F Translation Initiation Complex—New Opportunities for Cancer Treatment. <i>Clinical Cancer Research</i> , 2017, 23, 21-25.	3.2	75
186	Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management. <i>European Journal of Cancer</i> , 2019, 119, 97-106.	1.3	75
187	The new era of adjuvant therapies for melanoma. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 535-536.	12.5	73
188	Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. <i>European Journal of Cancer</i> , 2015, 51, 833-840.	1.3	71
189	4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9503-9503.	0.8	71
190	An epitranscriptomic mechanism underlies selective mRNA translation remodelling in melanoma persister cells. <i>Nature Communications</i> , 2019, 10, 5713.	5.8	70
191	Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): A pooled analysis.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9018-9018.	0.8	70
192	Immune Checkpoint Inhibitor Therapy Aggravates T Cell—Driven Plaque Inflammation in Atherosclerosis. <i>JACC: CardioOncology</i> , 2020, 2, 599-610.	1.7	69
193	ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee. <i>Annals of Oncology</i> , 2020, 31, 1449-1461.	0.6	69
194	Intratumoral Immunotherapy: From Trial Design to Clinical Practice. <i>Clinical Cancer Research</i> , 2021, 27, 665-679.	3.2	69
195	Immune Checkpoint Inhibitors in Melanoma Provide the Cornerstones for Curative Therapies. <i>Seminars in Oncology</i> , 2015, 42, 429-435.	0.8	68
196	Long-Term Protective Effect of Mature DC-LAMP+ Dendritic Cell Accumulation in Sentinel Lymph Nodes Containing Micrometastatic Melanoma. <i>Clinical Cancer Research</i> , 2007, 13, 3825-3830.	3.2	67
197	A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma. <i>Annals of Oncology</i> , 2015, 26, 2267-2274.	0.6	67
198	Renal effects of immune checkpoint inhibitors. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw382.	0.4	67

#	ARTICLE	IF	CITATIONS
199	Tumor destruction using electrochemotherapy followed by CpG oligodeoxynucleotide injection induces distant tumor responses. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 1291-1300.	2.0	65
200	Analysis and Characterization of Antitumor T-cell Response After Administration of Dendritic Cells Loaded With Allogeneic Tumor Lysate to Metastatic Melanoma Patients. <i>Journal of Immunotherapy</i> , 2008, 31, 101-112.	1.2	65
201	Severe meningo-radiculo-nevritis associated with ipilimumab. <i>Investigational New Drugs</i> , 2012, 30, 2407-2410.	1.2	64
202	Gene Electrotransfer of Plasmid Antiangiogenic Metargidin Peptide (AMEP) in Disseminated Melanoma: Safety and Efficacy Results of a Phase I First-in-Man Study. <i>Human Gene Therapy Clinical Development</i> , 2013, 24, 99-107.	3.2	64
203	Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. <i>European Journal of Cancer</i> , 2019, 116, 148-157.	1.3	64
204	Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600E/K mutant advanced or metastatic melanoma. <i>European Journal of Cancer</i> , 2019, 109, 61-69.	1.3	63
205	Subungual Splinter Hemorrhages: A Clinical Window to Inhibition of Vascular Endothelial Growth Factor Receptors?. <i>Annals of Internal Medicine</i> , 2005, 143, 313.	2.0	60
206	Management and outcome of metastatic melanoma during pregnancy. <i>British Journal of Dermatology</i> , 2010, 162, 274-281.	1.4	60
207	ICAM-1 Has a Critical Role in the Regulation of Metastatic Melanoma Tumor Susceptibility to CTL Lysis by Interfering with PI3K/AKT Pathway. <i>Cancer Research</i> , 2008, 68, 9854-9864.	0.4	59
208	Risk stratification of sentinel node-positive melanoma patients defines surgical management and adjuvant therapy treatment considerations. <i>European Journal of Cancer</i> , 2018, 96, 25-33.	1.3	59
209	KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. <i>Future Oncology</i> , 2020, 16, 4429-4438.	1.1	59
210	Efficacy of neoadjuvant cetuximab alone or with platinum salt for the treatment of unresectable advanced nonmetastatic cutaneous squamous cell carcinomas. <i>British Journal of Dermatology</i> , 2015, 173, 527-534.	1.4	58
211	Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/L1 therapy. <i>European Journal of Cancer</i> , 2016, 65, 33-42.	1.3	58
212	Immunotherapy discontinuation – how, and when? Data from melanoma as a paradigm. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 707-715.	12.5	57
213	Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. <i>European Journal of Cancer</i> , 2021, 144, 182-191.	1.3	57
214	Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study. <i>Lancet Oncology</i> , The, 2021, 22, 370-380.	5.1	57
215	3301 Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma. <i>European Journal of Cancer</i> , 2015, 51, S663.	1.3	56
216	LBA43 Spaltalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600E mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-hi trial. <i>Annals of Oncology</i> , 2020, 31, S1172.	0.6	56

#	ARTICLE	IF	CITATIONS
217	Targeted therapy-induced radiation recall. <i>European Journal of Cancer</i> , 2013, 49, 1662-1668.	1.3	55
218	Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. <i>Lancet Oncology</i> , The, 2014, 15, 297-304.	5.1	55
219	Immunization with recombinant MAGE-A3 protein combined with adjuvant systems AS15 or AS02B in patients with unresectable and progressive metastatic cutaneous melanoma: A randomized open-label phase II study of the EORTC Melanoma Group (16032- 18031). <i>Journal of Clinical Oncology</i> , 2008, 26, 9065-9065.	0.8	54
220	Vandetanib in Advanced Medullary Thyroid Cancer: Review of Adverse Event Management Strategies. <i>Advances in Therapy</i> , 2013, 30, 945-966.	1.3	53
221	Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9504-9504.	0.8	53
222	Two cases of immune thrombocytopenia associated with pembrolizumab. <i>European Journal of Cancer</i> , 2016, 54, 172-174.	1.3	52
223	New Era in the Management of Melanoma Brain Metastases. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 741-750.	1.8	52
224	Immune checkpoint inhibitors in melanoma in the metastatic, neoadjuvant, and adjuvant setting. <i>Current Opinion in Oncology</i> , 2020, 32, 106-113.	1.1	52
225	Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9005-9005.	0.8	52
226	Deleterious effects of ultraviolet A radiation in human cells. <i>Mutation Research DNA Repair</i> , 1997, 383, 1-8.	3.8	51
227	Tolerance and outcomes of stereotactic radiosurgery combined with anti-programmed cell death-1 (pembrolizumab) for melanoma brain metastases. <i>Melanoma Research</i> , 2018, 28, 111-119.	0.6	51
228	Tyrosine kinase inhibition and grey hair. <i>Lancet</i> , The, 2003, 361, 1056.	6.3	50
229	Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee survey. <i>ESMO Open</i> , 2018, 3, e000422.	2.0	50
230	Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 701-710.	5.1	50
231	PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma. <i>Nature Communications</i> , 2020, 11, 6262.	5.8	50
232	Hypopigmented mycosis fungoides. <i>Archives of Dermatology</i> , 1994, 130, 476-480.	1.7	50
233	A New Spectrum of Skin Toxic Effects Associated With the Multikinase Inhibitor Vandetanib. <i>Archives of Dermatology</i> , 2012, 148, 1418.	1.7	49
234	Epstein-Barr virus-associated lymphoproliferative disease during methotrexate therapy for psoriasis. <i>Archives of Dermatology</i> , 1997, 133, 867-871.	1.7	49

#	ARTICLE	IF	CITATIONS
235	Neutrophils, Monocytes, and Dendritic Cells Express the Same Specialized Form of PSGL-1 as Do Skin-Homing Memory T Cells: Cutaneous Lymphocyte Antigen. <i>Biochemical and Biophysical Research Communications</i> , 2001, 285, 577-587.	1.0	48
236	Sunitinib efficacy in the treatment of metastatic skin adnexal carcinomas: report of two patients with hidradenocarcinoma and trichoblastic carcinoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 199-203.	1.3	48
237	Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies. <i>British Journal of Cancer</i> , 2011, 105, 353-359.	2.9	48
238	Evaluation of the efficacy of immunotherapy for non-resectable mucosal melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1171-1178.	2.0	48
239	Gene expression signature associated with <i>BRAF</i> mutations in human primary cutaneous melanomas. <i>Molecular Oncology</i> , 2008, 1, 425-430.	2.1	47
240	Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study. <i>Annals of Oncology</i> , 2014, 25, 700-706.	0.6	47
241	Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2301-2312.	3.3	47
242	Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma. <i>JAMA Oncology</i> , 2020, 6, 1957.	3.4	46
243	Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. , 2021, 9, e001931.		46
244	Advances in the Management of Cutaneous Toxicities of Targeted Therapies. <i>Seminars in Oncology</i> , 2012, 39, 227-240.	0.8	45
245	Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E mutant cutaneous melanoma. <i>Annals of Oncology</i> , 2016, 27, vi575.	0.6	44
246	Secondary Tumors Arising in Patients Undergoing BRAF Inhibitor Therapy Exhibit Increased BRAF-CRAF Heterodimerization. <i>Cancer Research</i> , 2016, 76, 1476-1484.	0.4	44
247	Randomized phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 8510-8510.	0.8	44
248	Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival analysis of KEYNOTE-006.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9504-9504.	0.8	44
249	Is ulceration in cutaneous melanoma just a prognostic and predictive factor or is ulcerated melanoma a distinct biologic entity?. <i>Current Opinion in Oncology</i> , 2012, 24, 137-140.	1.1	43
250	Mast Cell Sarcoma: A Rare and Aggressive Entity—Report of Two Cases and Review of the Literature. <i>Journal of Clinical Oncology</i> , 2013, 31, e90-e97.	0.8	43
251	Regulation of CD4+NKG2D+ Th1 Cells in Patients with Metastatic Melanoma Treated with Sorafenib: Role of IL-15 and NKG2D Triggering. <i>Cancer Research</i> , 2014, 74, 68-80.	0.4	43
252	P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition. <i>European Journal of Cancer</i> , 2017, 83, 154-165.	1.3	42

#	ARTICLE	IF	CITATIONS
253	Correlation of Phenotype/Genotype in a Cohort of 23 Xeroderma Pigmentosum-Variant Patients Reveals 12 New Disease-Causing <i>POLH</i> Mutations. <i>Human Mutation</i> , 2014, 35, 117-128.	1.1	41
254	Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2019, 106, 106-114.	1.3	41
255	Bullous Amyloidosis. <i>Medicine (United States)</i> , 1993, 72, 38-44.	0.4	40
256	Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e67-e67.	0.5	40
257	Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma. , 2020, 8, e000391.		39
258	Harnessing the immune system to provide long-term survival in patients with melanoma and other solid tumors. <i>Oncolimmunology</i> , 2014, 3, e27560.	2.1	38
259	Association of <i>BRAF</i> V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma. <i>JAMA Oncology</i> , 2020, 6, 1256.	3.4	38
260	Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial. <i>Nature Medicine</i> , 2022, 28, 1224-1231.	15.2	38
261	Anti-CTLA-4 Antibody Adjuvant Therapy in Melanoma. <i>Seminars in Oncology</i> , 2010, 37, 455-459.	0.8	37
262	Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety. <i>Annals of Oncology</i> , 2012, 23, 1301-1306.	0.6	37
263	The 2016-2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study. <i>European Journal of Cancer</i> , 2020, 130, 39-50.	1.3	37
264	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 655-664.	5.1	37
265	The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients. <i>European Journal of Cancer</i> , 2021, 155, 268-280.	1.3	37
266	Management Of Tyrosine Kinase Inhibitor-Induced Hand-Foot Skin Reaction: Viewpoints from the Medical Oncologist, Dermatologist, and Oncology Nurse. <i>The Journal of Supportive Oncology</i> , 2011, 9, 13-23.	2.3	36
267	Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover. <i>Cancers</i> , 2020, 12, 1727.	1.7	36
268	Prevalence of sunbed use, and characteristics and knowledge of sunbed users: results from the French population-based difice melanoma survey. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 23-30.	1.3	35
269	Report on the status of women occupying leadership roles in oncology. <i>ESMO Open</i> , 2018, 3, e000423.	2.0	35
270	Older melanoma patients aged 75 and above retain responsiveness to anti-PD1 therapy: results of a retrospective single-institution cohort study. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1571-1578.	2.0	35

#	ARTICLE	IF	CITATIONS
271	Introduction of functional chimeric E/L-selectin by RNA electroporation to target dendritic cells from blood to lymph nodes. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 467-477.	2.0	33
272	Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: A randomized, open-label trial. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 1077-1085.	0.6	33
273	Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III. <i>European Journal of Cancer</i> , 2018, 91, 168-170.	1.3	33
274	Adjuvant Pembrolizumab in Resected Stage III Melanoma. <i>New England Journal of Medicine</i> , 2018, 379, 593-595.	13.9	33
275	Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation. <i>European Journal of Cancer</i> , 2021, 158, 208-216.	1.3	33
276	Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance. <i>Annals of Oncology</i> , 2021, 32, 1381-1390.	0.6	33
277	Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with <i>BRAF</i> V600-mutated Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2019, 25, 3239-3246.	3.2	32
278	A case of Rothmund-Thomson syndrome with reduced DNA repair capacity. <i>Archives of Dermatology</i> , 1993, 129, 332-336.	1.7	32
279	5-year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9516-9516.	0.8	32
280	Familial predisposition to TP53/complex karyotype MDS and leukemia in DNA repair-deficient xeroderma pigmentosum. <i>Blood</i> , 2019, 133, 2718-2724.	0.6	31
281	The anti-PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced <i>BRAF</i> V600 mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9531-9531.	0.8	31
282	Gap Junction Communication between Autologous Endothelial and Tumor Cells Induce Cross-Recognition and Elimination by Specific CTL. <i>Journal of Immunology</i> , 2009, 182, 2654-2664.	0.4	30
283	Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era. <i>Clinical Cancer Research</i> , 2020, 26, 4201-4205.	3.2	30
284	Five-year overall survival (OS) in COLUMBUS: A randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients (pts) with <i>BRAF</i> V600-mutant melanoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9507-9507.	0.8	30
285	Loss of Ambra1 promotes melanoma growth and invasion. <i>Nature Communications</i> , 2021, 12, 2550.	5.8	30
286	Redox activation of ATM enhances GSNOR translation to sustain mitophagy and tolerance to oxidative stress. <i>EMBO Reports</i> , 2021, 22, e50500.	2.0	30
287	A new paradigm tumor for drug development. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 74-76.	12.5	29
288	Phase I clinical trial combining imatinib mesylate and IL-2. <i>Oncolmmunology</i> , 2013, 2, e23080.	2.1	29

#	ARTICLE	IF	CITATIONS
289	Severe cutaneous adverse reaction associated with vemurafenib: <scp>DRESS</scp>, <scp> AGEP</scp> or overlap reaction?. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 178-179.	1.3	29
290	Vemurafenib Cooperates with HPV to Promote Initiation of Cutaneous Tumors. Cancer Research, 2014, 74, 2238-2245.	0.4	28
291	Is earlier better for melanoma checkpoint blockade?. Nature Medicine, 2018, 24, 1645-1648.	15.2	28
292	Cetuximab is efficient and safe in patients with advanced cutaneous squamous cell carcinoma: a retrospective, multicentre study. Oncotarget, 2020, 11, 378-385.	0.8	28
293	Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. European Journal of Cancer, 2022, 162, 22-33.	1.3	28
294	Update on the role of ipilimumab in melanoma and first data on new combination therapies. Current Opinion in Oncology, 2013, 25, 166-172.	1.1	27
295	Severe ophthalmoplegia and myocarditis following the administration of pembrolizumab. European Journal of Cancer, 2018, 91, 171-173.	1.3	27
296	Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis. British Journal of Cancer, 2021, 124, 574-580.	2.9	27
297	Practical considerations in the management of hand-foot skin reaction caused by multikinase inhibitors. Community Oncology, 2010, 7, 23-29.	0.2	26
298	Mechanisms of skin aging induced by EGFR inhibitors. Supportive Care in Cancer, 2016, 24, 4241-4248.	1.0	26
299	Characterization of complete responses (CRs) in patients with advanced melanoma (MEL) who received the combination of nivolumab (NIVO) and ipilimumab (IPI), NIVO or IPI alone. Annals of Oncology, 2017, 28, v428.	0.6	26
300	Arterial thrombosis and anti-PD-1 blockade. European Journal of Cancer, 2018, 91, 164-166.	1.3	26
301	Interventional Radiology for Local Immunotherapy in Oncology. Clinical Cancer Research, 2021, 27, 2698-2705.	3.2	26
302	The interval between primary melanoma excision and sentinel node biopsy is not associated with survival in sentinel node positive patients " An EORTC Melanoma Group study. European Journal of Surgical Oncology, 2016, 42, 1906-1913.	0.5	25
303	Impact of COVID-19 on healthcare organisation and cancer outcomes. European Journal of Cancer, 2021, 153, 123-132.	1.3	25
304	Gene therapy to target dendritic cells from blood to lymph nodes. Gene Therapy, 2003, 10, 1479-1486.	2.3	24
305	Thyroid adenomas and carcinomas following radiotherapy for a hemangioma during infancy. Radiotherapy and Oncology, 2009, 93, 377-382.	0.3	24
306	Effect of time to sentinel-node biopsy on the prognosis of cutaneous melanoma. European Journal of Cancer, 2015, 51, 1780-1793.	1.3	24

#	ARTICLE	IF	CITATIONS
307	Malignant melanoma and granulomatosis. <i>British Journal of Dermatology</i> , 1997, 137, 787-792.	1.4	24
308	BREAK-MB: A phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/k mutation-positive melanoma with brain metastases (mets).. <i>Journal of Clinical Oncology</i> , 2012, 30, 8501-8501.	0.8	24
309	Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9004-9004.	0.8	24
310	Molecular Characterization and Patient Outcome of Melanoma Nodal Metastases and an Unknown Primary Site. <i>Annals of Surgical Oncology</i> , 2014, 21, 4317-4323.	0.7	23
311	A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma. <i>Journal of Translational Medicine</i> , 2015, 13, O5.	1.8	23
312	Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora?. <i>Seminars in Immunopathology</i> , 2017, 39, 327-331.	2.8	22
313	Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives. <i>British Journal of Cancer</i> , 2020, 123, 885-897.	2.9	22
314	The evolving field of Dermatooncology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDV, UEMS and EORTC Cutaneous Lymphoma Task Force. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2183-2197.	1.3	22
315	Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3015-3015.	0.8	22
316	Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).. <i>Journal of Clinical Oncology</i> , 2014, 32, LBA9000-LBA9000.	0.8	22
317	Transcriptional response to hypoxic stress in melanoma and prognostic potential of GBE1 and BNIP3. <i>Oncotarget</i> , 2017, 8, 108786-108801.	0.8	22
318	Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study. <i>Annals of Oncology</i> , 2022, 33, 968-980.	0.6	22
319	Cutaneous malignant melanoma in children and adolescents treated in pediatric oncology units. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1922-1927.	0.8	21
320	Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules. <i>Clinical Cancer Research</i> , 2021, 27, 5280-5288.	3.2	21
321	Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: New recurrence-free survival results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial at three-year median follow-up.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10000-10000.	0.8	21
322	Smart therapeutic strategies in immuno-oncology. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 181-182.	12.5	20
323	Acute Lower Limb Ischaemia and Diabetes in a Patient Treated with Anti-PD1 Monoclonal Antibody for Metastatic Melanoma. <i>Acta Dermato-Venereologica</i> , 2017, 97, 408-409.	0.6	20
324	LAG-3 and PD-1 blockade raises the bar for melanoma. <i>Nature Cancer</i> , 2021, 2, 1251-1253.	5.7	20

#	ARTICLE	IF	CITATIONS
325	Adverse events 2.0â€”Let us get SERIOs. <i>European Journal of Cancer</i> , 2019, 112, 29-31.	1.3	19
326	Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. <i>European Journal of Cancer</i> , 2021, 158, 156-168.	1.3	19
327	Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 53-61.	1.1	18
328	The challenge to bring personalized cancer medicine from clinical trials into routine clinical practice: The case of the Institut Gustave Roussy. <i>Molecular Oncology</i> , 2012, 6, 204-210.	2.1	18
329	Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients. <i>OncImmunology</i> , 2013, 2, e23079.	2.1	18
330	Pregnancy and melanoma: a Europeanâ€”wide survey to assess current management and a critical literature overview. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 65-69.	1.3	18
331	Ipilimumab versus placebo after complete resection of stage III melanoma: Long-term follow-up results the EORTC 18071 double-blind phase 3 randomized trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2512-2512.	0.8	18
332	Immature mouse dendritic cells enter inflamed tissue, a process that requires E- and P-selectin, but not P-selectin glycoprotein ligand 1. <i>Blood</i> , 2002, 99, 946-956.	0.6	18
333	Prognostic and predictive value of Î²-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. <i>European Journal of Cancer</i> , 2022, 165, 97-112.	1.3	18
334	Who Benefits Most From Adjuvant Interferon Treatment for Melanoma?. <i>American Journal of Therapeutics</i> , 2015, 22, 54-60.	0.5	17
335	Do immune checkpoint inhibitors perform identically in patients with weight extremes?. <i>Immunotherapy</i> , 2018, 10, 733-736.	1.0	17
336	Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Antiâ€”PD-1 Therapy. <i>JCO Precision Oncology</i> , 2021, 5, 1821-1829.	1.5	17
337	Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlus. <i>European Journal of Cancer</i> , 2022, 163, 79-87.	1.3	17
338	Pembrolizumab (Pembro; Mk-3475) for Advanced Melanoma (Mel): Randomized Comparison of Two Dosing Schedules. <i>Annals of Oncology</i> , 2014, 25, v1.	0.6	16
339	Outcomes of patients with cancer and sarcoid-like granulomatosis associated with immune checkpoint inhibitors: A caseâ€”control study. <i>European Journal of Cancer</i> , 2021, 156, 46-59.	1.3	16
340	A phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 9023-9023.	0.8	16
341	A prospective coagulation study including resistance to activated protein C and mutations in factors V and II in venous leg ulcers. <i>British Journal of Dermatology</i> , 1999, 141, 259-263.	1.4	15
342	PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): A pooled analysis. <i>Annals of Oncology</i> , 2016, 27, vi381.	0.6	15

#	ARTICLE	IF	CITATIONS
343	Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature. <i>ESMO Open</i> , 2017, 2, e000203.	2.0	15
344	Sentinel lymph node biopsy in cutaneous head and neck melanoma. <i>European Archives of Oto-Rhino-Laryngology</i> , 2018, 275, 1271-1279.	0.8	15
345	Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers. <i>European Journal of Cancer</i> , 2021, 153, 234-241.	1.3	15
346	Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies. , 2022, 10, e003024.		15
347	Hypopigmented mycosis fungoides in a light-skinned woman. <i>British Journal of Dermatology</i> , 1998, 139, 341-343.	1.4	14
348	Longitudinal subungual acanthoma: one denomination for various clinical presentations. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1608-1613.	1.3	14
349	The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials. <i>Melanoma Research</i> , 2021, 31, 181-185.	0.6	14
350	Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, LBA9008-LBA9008.	0.8	14
351	Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600-mutant melanoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10012-10012.	0.8	14
352	Successful repetitive treatments by electrochemotherapy of multiple unresectable Kaposi sarcoma nodules. <i>European Journal of Cancer, Supplement</i> , 2006, 4, 29-31.	2.2	13
353	Comparison of sun protection modalities in parents and children. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 16-19.	1.3	13
354	Sun exposure profile in the French population. Results of the EDIFICE Melanoma survey. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 6-10.	1.3	13
355	The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel study. <i>Melanoma Research</i> , 2018, 28, 333-340.	0.6	13
356	Risk-based stratification in head and neck mucosal melanoma. <i>Oral Oncology</i> , 2019, 97, 44-49.	0.8	13
357	Dose escalation phase 1 study of radiotherapy in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 monoclonal antibody ipilimumab in patients with metastatic melanoma. , 2020, 8, e000627.		13
358	Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trial. <i>European Journal of Cancer</i> , 2020, 133, 94-103.	1.3	13
359	Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006. <i>European Journal of Cancer</i> , 2021, 157, 391-402.	1.3	13
360	HIV-negative patient with HHV-8 DNA follicular B-cell lymphoma associated with Kaposi's sarcoma. <i>Lancet, The</i> , 1996, 347, 1042-1043.	6.3	12

#	ARTICLE	IF	CITATIONS
361	Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma. <i>Journal of Translational Medicine</i> , 2015, 13, .	1.8	12
362	Impact of dermatologic adverse events induced by targeted therapies on quality of life. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 101, 158-168.	2.0	12
363	Melanoma and immunotherapy bridge 2015. <i>Journal of Translational Medicine</i> , 2016, 14, 65.	1.8	12
364	Melanoma during fingolimod treatment for multiple sclerosis. <i>European Journal of Cancer</i> , 2019, 113, 75-77.	1.3	12
365	Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAFV600 mutationâ€“positive melanoma. <i>Annals of Oncology</i> , 2022, 33, 544-555.	0.6	12
366	Side Effects and Toxicities of Targeted Therapies in Stage IV Melanoma. <i>American Journal of Therapeutics</i> , 2015, 22, 44-53.	0.5	11
367	Synergistic effects of eIF4A and MEK inhibitors on proliferation of NRAS-mutant melanoma cell lines. <i>Cell Cycle</i> , 2016, 15, 2405-2409.	1.3	11
368	Clinical outcomes after interstitial brachytherapy for early-stage nasal squamous cell carcinoma. <i>Brachytherapy</i> , 2017, 16, 1021-1027.	0.2	11
369	One or Two Immune Checkpoint Inhibitors?. <i>Cancer Cell</i> , 2019, 36, 579-581.	7.7	11
370	The EORTC-DeCOG nomogram adequately predicts outcomes of patients with sentinel nodeâ€“positive melanoma without the need for completion lymph node dissection. <i>European Journal of Cancer</i> , 2020, 134, 9-18.	1.3	11
371	Patient Experiences with Avelumab in Treatment-Naïve Metastatic Merkel Cell Carcinoma: Longitudinal Qualitative Interview Findings from JAVELIN Merkel 200, a Registrational Clinical Trial. <i>Patient</i> , 2020, 13, 457-467.	1.1	11
372	The Role of mRNA Translational Control in Tumor Immune Escape and Immunotherapy Resistance. <i>Cancer Research</i> , 2021, 81, 5596-5604.	0.4	11
373	Randomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-3475 for ipilimumab-refractory (IPI-R) and IPI-naïve (IPI-N) melanoma (MEL).. <i>Journal of Clinical Oncology</i> , 2014, 32, 3000-3000.	0.8	11
374	How cutaneous eruptions help to understand the mode of action of kinase inhibitors. <i>British Journal of Dermatology</i> , 2012, 167, 965-967.	1.4	10
375	Dramatic response to radiotherapy combined with vemurafenib. Is vemurafenib a radiosensitizer?. <i>European Journal of Dermatology</i> , 2014, 24, 265-267.	0.3	10
376	Evolution of sunâ€“protection measures for children. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 20-22.	1.3	10
377	Expanded access programmes: patient interests versus clinical trial integrity. <i>Lancet Oncology</i> , The, 2015, 16, 15-17.	5.1	10
378	A Novel Spectroscopically Determined Pharmacodynamic Biomarker for Skin Toxicity in Cancer Patients Treated with Targeted Agents. <i>Cancer Research</i> , 2017, 77, 557-565.	0.4	10

#	ARTICLE	IF	CITATIONS
379	P315 Gastrointestinal immune related adverse events associated with programmed-Death 1 blockade. <i>Journal of Crohn's and Colitis</i> , 2017, 11, S237-S237.	0.6	10
380	Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial. <i>European Radiology</i> , 2021, 31, 1853-1862.	2.3	10
381	Abscopal antitumor effect in a patient with melanoma and coronavirus disease 2019. <i>European Journal of Cancer</i> , 2021, 149, 91-93.	1.3	10
382	EDIFICE Melanoma survey: knowledge and attitudes on melanoma prevention and diagnosis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 11-15.	1.3	9
383	Treatment Algorithms in Stage IV Melanoma. <i>American Journal of Therapeutics</i> , 2015, 22, 61-67.	0.5	9
384	Post-shingles granulomatous dermatosis related to anti-programmed cell death 1. <i>Immunotherapy</i> , 2019, 11, 591-598.	1.0	9
385	Efficacy, safety and factors associated with disease progression in patients with unresectable (stage) T1-T4b melanoma: Overall survival (OS) and quality of life (QoL) in the phase III study of trametinib in combination with dabrafenib. <i>European Journal of Cancer</i> , 2021, 154, 57-65.	1.3	9
386	Effect on health-related quality of life (HRQOL) of adjuvant treatment (tx) with dabrafenib plus trametinib (D + T) in patients (pts) with resected stage III BRAF<i>V600E</i>-mutant melanoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 9590-9590.	0.8	9
387	STARBOARD: encorafenib+binimetinib+ pembrolizumab for first-line metastatic/unresectable BRAF<i>V600E</i>-mutant melanoma. <i>Future Oncology</i> , 2022, 18, 2041-2051.	1.1	9
388	Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF<i>V600E</i>-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i). <i>Journal of Clinical Oncology</i> , 2022, 10, e004226.		9
389	Sarcoid-like Granulomatosis Associated with Immune Checkpoint Inhibitors in Melanoma. <i>Cancers</i> , 2022, 14, 2937.	1.7	9
390	Malignant Hypercalcemia Induced by a Parathyroid Hormone-Related Protein Secreted by a Cutaneous Squamous Cell Carcinoma. <i>Archives of Dermatology</i> , 1997, 133, 113.	1.7	8
391	Regulation of gap junctions in melanoma and their impact on Melan-A/MART-1-specific CD8+ T lymphocyte emergence. <i>Journal of Molecular Medicine</i> , 2013, 91, 1207-1220.	1.7	8
392	Systemic Therapy Options for Patients With Unresectable Melanoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 661-672.	1.8	8
393	Management of Sentinel-Node Metastasis in Melanoma. <i>New England Journal of Medicine</i> , 2018, 378, 85-88.	13.9	8
394	Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib. <i>Clinical Cancer Research</i> , 2021, 27, 4500-4510.	3.2	8
395	Breast cancer following radiotherapy for a hemangioma during childhood. <i>Cancer Causes and Control</i> , 2010, 21, 1807-1816.	0.8	7
396	Radiotherapy as a risk factor for malignant melanoma after childhood skin hemangioma. <i>Melanoma Research</i> , 2012, 22, 77-85.	0.6	7

#	ARTICLE	IF	CITATIONS
397	Checkpoint Blockade Plus Oncolytic Virus: A Hot Therapeutic Cancer Strategy. Trends in Molecular Medicine, 2017, 23, 983-985.	3.5	7
398	Asymmetric Acral Spared Phenomenon Related to Systemic Anticancer Therapies. Skin Appendage Disorders, 2018, 4, 315-319.	0.5	7
399	Health-related quality-of-life results for pembrolizumab versus placebo after complete resection of high-risk stage III melanoma from the EORTC 1325-MG/Keynote 054 trial: An international randomized double-blind phase III trial. Annals of Oncology, 2018, 29, viii456.	0.6	7
400	Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS). European Journal of Cancer, 2021, 152, 116-128.	1.3	7
401	Can radiation-recall predict long lasting response to immune checkpoint inhibitors?. Radiotherapy and Oncology, 2021, 154, 125-127.	0.3	7
402	Abstract CT012: Evaluation of atezolizumab (A), cobimetinib (C), and vemurafenib (V) in previously untreated patients with BRAFV600mutation-positive advanced melanoma: Primary results from the phase 3 IMspire150 trial. , 2020, , .		7
403	Pooled analysis of safety over time and link between adverse events and efficacy across combination dabrafenib and trametinib (D+T) registration trials.. Journal of Clinical Oncology, 2016, 34, 9534-9534.	0.8	7
404	A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma. Clinical Cancer Research, 2022, 28, 518-525.	3.2	7
405	Assessment of various efficacy outcomes using ERIVANCE-like criteria in patients with locally advanced basal cell carcinoma receiving sonidegib: results from a preplanned sensitivity analysis. BMC Cancer, 2021, 21, 1244.	1.1	7
406	Feasibility, safety and efficacy of human intra-tumoral immuno-therapy. Gustave Roussy's initial experience with its first 100 patients. European Journal of Cancer, 2022, 172, 1-12.	1.3	7
407	Four-Year Survival Update for Metastatic Melanoma (MM) Patients (PTS) Treated with Ipilimumab (IPI) + Dacarbazine (DTIC) on Phase 3 Study CA184-024. Annals of Oncology, 2012, 23, ix367.	0.6	6
408	Sorafenib plus dacarbazine in solid tumors: a phase I study with dynamic contrast-enhanced ultrasonography and genomic analysis of sequential tumor biopsy samples. Investigational New Drugs, 2014, 32, 312-322.	1.2	6
409	Pulmonary nodules and immunotherapy: disease progression or toxicity of anti-PD1/anti-PDL1 checkpoint inhibitors?. European Journal of Cancer, 2018, 93, 144-146.	1.3	6
410	Neurotoxicity induced by targeted therapies in patients treated for metastatic melanoma. European Journal of Cancer, 2019, 111, 8-11.	1.3	6
411	Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review. Melanoma Management, 2019, 6, MMT33.	0.1	6
412	Prognostic value and therapeutic implications of nodal involvement in head and neck mucosal melanoma. Head and Neck, 2021, 43, 2325-2331.	0.9	6
413	Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inhibitor to screen cardiac or neuromuscular immune-related toxicities. European Journal of Cancer, 2021, 157, 383-390.	1.3	6
414	Melanoma recurrence after adjuvant targeted therapy: A multicenter analysis.. Journal of Clinical Oncology, 2020, 38, 10016-10016.	0.8	6

#	ARTICLE	IF	CITATIONS
415	Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 1422-1432.	3.2	6
416	Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma. <i>Cancers</i> , 2022, 14, 2300.	1.7	6
417	Timing of completion lymphadenectomy after positive sentinel node biopsy in patients with melanoma. <i>British Journal of Surgery</i> , 2017, 104, 726-733.	0.1	5
418	Boosting Immunity by Targeting Post-translational Prenylation of Small GTPases. <i>Cell</i> , 2018, 175, 901-902.	13.5	5
419	Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administrationâ€”Melanoma Research Alliance Public Workshop. <i>Clinical Cancer Research</i> , 2021, 27, 394-401.	3.2	5
420	Effectiveness and safety of nivolumab in patients with advanced melanoma: A multicenter, observational study. <i>International Journal of Cancer</i> , 2021, 148, 2789-2798.	2.3	5
421	Antitumor Activity of Ipilimumab or BRAF ± MEK Inhibition After Pembrolizumab in Patients With Advanced Melanoma: Analysis from KEYNOTE-006. <i>Annals of Oncology</i> , 2021, , .	0.6	5
422	Differential Effects on the Translation of Immune-Related Alternatively Polyadenylated mRNAs in Melanoma and T Cells by eIF4A Inhibition. <i>Cancers</i> , 2022, 14, 1177.	1.7	5
423	Molecular pathology of cutaneous melanoma. <i>Melanoma Management</i> , 2014, 1, 151-164.	0.1	4
424	MAP-kinase pathway up or down? Just look at the skin of your patients!. <i>Melanoma Research</i> , 2014, 24, 421-423.	0.6	4
425	Personal vs. intrinsic melanoma risk awareness: results of the EDIFICE Melanoma survey. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 31-34.	1.3	4
426	Impact of Skin Toxicities Associated with Targeted Cancer Therapies on Body Image: A Prospective Study. <i>Clinical Drug Investigation</i> , 2016, 36, 235-242.	1.1	4
427	Sentinel lymph node biopsy in 33 nonâ€”melanoma skin cancers of the head and neck: A twelveâ€”year experience with longâ€”term followâ€”up. <i>Clinical Otolaryngology</i> , 2018, 43, 1148-1152.	0.6	4
428	Upregulation of intratumoral HLA class I and peritumoral Mx1 in ulcerated melanomas. <i>Oncolmmunology</i> , 2019, 8, e1660121.	2.1	4
429	MÃ©lanome â€” ThÃ©rapeutique par les mÃ©dications : anticorps anti-CTLA-4 et anti-PD1. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2014, 198, 297-308.	0.0	4
430	Folliculitis and perionyxis associated with the EGFR inhibitor erlotinib. <i>Targeted Oncology</i> , 2006, 1, 100-103.	1.7	3
431	Melanoma risk-takers: fathers and sons. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 35-38.	1.3	3
432	Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trial. <i>Annals of Oncology</i> , 2018, 29, viii446.	0.6	3

#	ARTICLE	IF	CITATIONS
433	Elevated Levels of <i>BRAF</i> ^{V600} Mutant Circulating Tumor DNA and Circulating Hepatocyte Growth Factor Are Associated With Poor Prognosis in Patients With Metastatic Melanoma. <i>JCO Precision Oncology</i> , 2018, 2, 1-17.	1.5	3
434	Multi-omics prediction in melanoma immunotherapy: A new brick in the wall. <i>Cancer Cell</i> , 2022, 40, 14-16.	7.7	3
435	Neuropilin-1 cooperates with PD-1 in CD8+ T cells predicting outcomes in melanoma patients treated with anti-PD1. <i>IScience</i> , 2022, 25, 104353.	1.9	3
436	Health-related quality of life (HRQoL) with pembrolizumab (pembro) in resected high-risk stage II melanoma in the phase 3 KEYNOTE-716 study. <i>Journal of Clinical Oncology</i> , 2022, 40, 9581-9581.	0.8	3
437	Twenty-two cutaneous primary melanomas in a patient with high genetic predisposition to melanoma receiving levodopa therapy for Parkinson's disease. <i>Pigment Cell and Melanoma Research</i> , 2009, 22, 851-853.	1.5	2
438	P202 Ipilimumab colitis: a GETAID multicentric study. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S146.	0.6	2
439	Successful re-challenge with anti-BRAF and anti-MEK in a patient with symptomatic melanoma flare. <i>European Journal of Cancer</i> , 2017, 82, 25-26.	1.3	2
440	Reply to: "Incidence of grade 3-4 liver injury under immune checkpoints inhibitors: A retrospective study". <i>Journal of Hepatology</i> , 2018, 69, 1397-1398.	1.8	2
441	Estimating causal effects of time-dependent exposures on a binary endpoint in a high-dimensional setting. <i>BMC Medical Research Methodology</i> , 2018, 18, 67.	1.4	2
442	Reply to: "Immune-related hepatitis with immunotherapy: Are corticosteroids always needed?". <i>Journal of Hepatology</i> , 2018, 69, 550-551.	1.8	2
443	Acute pancreatitis after vismodegib for basal cell carcinoma: a causal relation?. <i>European Journal of Cancer</i> , 2019, 118, 67-69.	1.3	2
444	Adverse event (AE) kinetics in patients (pts) treated with dabrafenib + trametinib (D + T) in the metastatic and adjuvant setting. <i>Annals of Oncology</i> , 2019, 30, v543-v544.	0.6	2
445	BRAF exon 11 mutant melanoma and sensitivity to BRAF/MEK inhibition: Two case reports. <i>European Journal of Cancer</i> , 2019, 121, 109-112.	1.3	2
446	Reply to: "Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies?". <i>Journal of Hepatology</i> , 2019, 70, 566-567.	1.8	2
447	Combination of targeted therapy and immune checkpoint blocker in a patient with xeroderma pigmentosum presenting an aggressive angiosarcoma and a recurrent non-resectable basal cell carcinoma. <i>European Journal of Cancer</i> , 2021, 150, 130-132.	1.3	2
448	Adjuvant therapy in stage IIIA melanoma - Authors' reply. <i>Lancet Oncology</i> , The, 2021, 22, e300.	5.1	2
449	Multiple immune-related toxicities in cancer patients treated with anti-programmed cell death protein 1 immunotherapies: a new surrogate marker for clinical trials?. <i>Annals of Oncology</i> , 2021, 32, 936-937.	0.6	2
450	Doppler-Ultrasonography with perfusion software and contrast medium injection as an early evaluation tool of gastro intestinal stromal tumor (GIST) treated by imatinib: Results of a prospective study. <i>Journal of Clinical Oncology</i> , 2004, 22, 9048-9048.	0.8	2

#	ARTICLE	IF	CITATIONS
451	Patient-reported outcomes (PROs) in KEYNOTE-002, a randomized study of pembrolizumab vs chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) metastatic melanoma (MEL).. Journal of Clinical Oncology, 2015, 33, 9040-9040.	0.8	2
452	Seminal vesicle metastasis of cutaneous malignant melanoma : an unusual and challenging presentation.. Canadian Urological Association Journal, 2015, 9, 220.	0.3	2
453	Keratoacanthoma or cutaneous squamous cell carcinoma revealing a DNA mismatch repair defect (Muir-Torre Syndrome). Journal of the European Academy of Dermatology and Venereology, 2022, 36, 74-76.	1.3	2
454	Hypermetabolic dermatofibroma on Positron Emission Tomography/Computed tomography with 18F-FluoroDeoxyGlucose : a misleading false positive in the follow-up of a metastatic melanoma. European Journal of Dermatology, 2008, 18, 461-2.	0.3	2
455	Visceral lesions occurring during follow-up of melanoma patients: a true place for other diagnosis than melanoma metastasis. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 602-610.	1.3	1
456	Metastatic melanoma: New paradigms of treatment and new toxicities. European Journal of Cancer, Supplement, 2013, 11, 278-280.	2.2	1
457	Association of homogeneous inflamed gene signature with a better outcome in patients with metastatic melanoma treated with MAGE-A3 immunotherapeutic. ESMO Open, 2018, 3, e000384.	2.0	1
458	Reply to E. Hindi and K.R. Hess. Journal of Clinical Oncology, 2019, 37, 1356-1358.	0.8	1
459	Reply to E. Hindi. Journal of Clinical Oncology, 2021, 39, 944-946.	0.8	1
460	Association of Adjuvant Immunotherapy Duration With Chronic Immune-Related Adverse Events. JAMA Oncology, 2021, 7, 1573-1574.	3.4	1
461	In situ detection of the eIF4F translation initiation complex in mammalian cells and tissues. STAR Protocols, 2021, 2, 100621.	0.5	1
462	Troponin increase during immunotherapy: Not always myocarditis. European Journal of Cancer, 2021, 157, 424-427.	1.3	1
463	Refractive changes during immunotherapy: Think diabetes!. European Journal of Cancer, 2021, 158, 15-16.	1.3	1
464	Dermatologic Side Effects of Systemic Anticancer Therapy. , 2013, , 381-419.		1
465	Molecular testing in Cutaneous Melanoma. , 2014, , 363-374.		1
466	First case of a melanocytic intrabulbar brain tumour treated with bevacizumab. European Journal of Cancer, 2022, 162, 206-208.	1.3	1
467	Homing receptors: potential therapeutical tools?. Experimental Dermatology, 2002, 11, 472-473.	1.4	0
468	Commenter au mieux la toxicité des traitements antiangiogéniques?. , 2008, , 197-205.		0

#	ARTICLE	IF	CITATIONS
469	Drug-induced Nail Changes. , 2012, , 413-442.		0
470	EORTC Melanoma Group achievements. European Journal of Cancer, Supplement, 2012, 10, 112-119.	2.2	0
471	Métastase sous-cutané jugale de mélanome malin. Annales Francaises D'Oto-Rhino-Laryngologie Et De Pathologie Cervico-Faciale, 2014, 131, 176-178.	0.0	0
472	Hypodermal metastasis of malignant melanoma to the cheek. European Annals of Otorhinolaryngology, Head and Neck Diseases, 2014, 131, 189-191.	0.4	0
473	Development of Novel Anticancer Agents that Target Prohibitins and the Translation Initiation Factor eIF4A. Annals of Oncology, 2015, 26, ii25.	0.6	0
474	Melanoma cutané cervicofacial. EMC - Otorrinolaringología, 2017, 46, 1-9.	0.0	0
475	Melanomi cutanei cervicofacciali. EMC - Otorinolaringoiatria, 2017, 16, 1-9.	0.0	0
476	Concerning the article by Louveuet al "Clinical value of early detection of circulating tumour DNA BRAFV600mut in patients with metastatic melanoma treated with a BRAF inhibitor". ESMO Open, 2017, 2, e000207.	2.0	0
477	Melanoma: Immunotherapy in Advanced Melanoma and in the Adjuvant Setting. , 2018, , 579-591.		0
478	Anticancer Therapies. , 0, , 604-616.		0
479	Dermatologic Side Effects of Systemic Targeted Anticancer Therapy. , 2018, , 285-313.		0
480	Reply to: "Mortality due to immunotherapy related hepatitis". Journal of Hepatology, 2018, 69, 978-979.	1.8	0
481	Mitochondrial myopathy associated with anti-programmed cell death 1 therapy. European Journal of Cancer, 2019, 110, 71-73.	1.3	0
482	Is it melanoma? Ask my dog!. Melanoma Research, 2020, 30, 529-530.	0.6	0
483	Combining tumor destruction by electrochemotherapy and innate immunity by CpG-ODN: Toward a new combination treatment for melanoma with skin metastases. Journal of Clinical Oncology, 2006, 24, 12507-12507.	0.8	0
484	Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma. An EORTC Melanoma group study. Journal of Clinical Oncology, 2007, 25, 8509-8509.	0.8	0
485	Immunotherapy of Melanoma: A New Era. , 2011, , 359-372.		0
486	Dermatologic Manifestations of Systemic Oncologic Therapy of Cutaneous Malignancies. , 2011, , 379-385.		0

#	ARTICLE	IF	CITATIONS
487	Immune Checkpoint Inhibitors in Melanoma Define a New Era in Immunotherapy Aiming for Cure. , 2017, , 427-436.		0
488	Discovery of Iminobenzimidazole Derivatives as Novel Cytotoxic Agents. Open Medicinal Chemistry Journal, 2018, 12, 74-83.	0.9	0
489	Dermatological Complications of Systemic Therapies for Melanoma. , 2019, , 1-22.		0
490	Hematologic Toxicities of Apparent Immune-Related Origins. , 2019, , .		0
491	Management of Melanoma Brain Metastasis. , 2020, , 281-287.		0
492	Dermatological Complications of Systemic Therapies for Melanoma. , 2020, , 1337-1358.		0
493	Bariatric surgery in a patient treated with targeted therapies for metastatic melanoma: a case report. Melanoma Research, 2020, 30, 629-630.	0.6	0
494	The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021. Journal of Translational Medicine, 2022, 20, 200.	1.8	0